Implementation of Risk Minimization Action
Plans to Support Quality Use of
Pharmaceuticals; Opportunities and
Challenges:
A Public Workshop
June 25 and 26, 2007

Panel 1
Patient Advocacy and Consumer Groups

Chair: Terry Toigo, R.Ph., M.B.A.

Workshop Objectives

- 1. Initiate constructive dialogue and information-sharing.
- 2. Share key lessons learned.
- 3. Explore how tools being actively developed may improve the development of RiskMAPs.

Panel 1 – Patient Advocacy and Consumer Groups

Mrs. Cheryl Bloom Former Moderator, MS World

Mr. Ken Makowka
Fairfield County Multiple Myeloma Support Group

Ms. Amy Allina
National Women's Health Network

Mr. William Vaughn Consumer's Union

Questions

- What do people perceive as the tradeoffs between the burdens of the programs and benefits of using the products? How do they impact access to products?
- Do the RiskMap programs encourage or discourage patients to seek use of the products? Do they enable the products to be used as intended?
- How effective are the various reminder tools? What recommendations would you make for improving implementation and use of reminder tools?
- What costs (financial, convenience, etc) are there to performance linked access programs? How have people managed the costs? How can PLAS's be improved to minimize costs to patients?